跳至主要内容
临床试验/NCT00965419
NCT00965419终止2 期

Long-Term, Open-Label, Safety Study of LY2216684 in Pediatric Patients With Attention Deficit/Hyperactivity Disorder

Eli Lilly and Company1 个研究点 分布在 1 个国家目标入组 267 人开始时间: 2009年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
终止
入组人数
267
试验地点
1
主要终点
Percentage of Participants With At Least One Serious Adverse Events (SAE) Over the Duration of the Study

研究概览

简要总结

The primary purpose of the study is to assess long-term safety and tolerability of Edivoxetine in pediatric participants with attention deficit hyperactive disorder (ADHD).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
6 Years 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Edivoxetine

Experimental

All enrolled participants were administered starting dose of 0.1 milligram per kilogram per day (mg/kg/day), or participant specific known stable dose, rollover participants (LNBJ [No NCT number]) and (LNBF [NCT00922636]), up to 0.3 mg/kg/day, oral, daily for up to 5 years.

干预措施: Edivoxetine (Drug)

结局指标

主要结局

Percentage of Participants With At Least One Serious Adverse Events (SAE) Over the Duration of the Study

时间窗: Baseline Through Week 252

Percentage of Participants experienced at least one SAE during the study. A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.

Number of Participants With At Least One SAE

时间窗: Baseline Through Week 252

Number of Participants experienced at least one SAE during the study. A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.

次要结局

  • Mean Change From Baseline Z-scores for Height(Baseline, Week 60; Baseline, Week 240)
  • Number of Participants Who Discontinued Due to Any Reason(Baseline Through Week 252)
  • Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)(Baseline Through Week 252)
  • Number of Participants With At Least One TEAE(Baseline Through Week 252)
  • Percentage of Participants With Discontinuation Due to Adverse Events (DCAEs)(Baseline Through Week 252)
  • Number of Participants With At Least One DCAEs(Baseline Through Week 252)
  • Percentage of Participants Who Discontinued Due to Any Reason(Baseline Through Week 252)
  • Percentage of Participants With Columbia-Suicide Severity Rating Scale (CSSRS) for Each Category(Baseline Through Week 252, Baseline, 1-month (mo) Follow-Up (f/u))
  • Mean Change From Baseline Z-Score for Weight(Baseline, Week 60; Baseline, Week 240)
  • Mean Change From Baseline Z-Score in Body Mass Index (BMI)(Baseline, Week 60; Baseline, Week 240)
  • Number of Participants With a Response Rate(Week 12)
  • Survival Curve Time to Response(Week 12)
  • Percentage of Participants in Sexual Maturation on Tanners Scale(Baseline Up to Week 252)
  • Number of Participants in Sexual Maturation on Tanners Scale(Baseline Up to Week 252)
  • Percentage of Participants With Response Rates(Week 12)
  • Mean Change From Baseline of Total Score SNAP-IV Oppositional Defiant Disorder (ODD) Subscale(Baseline, Week 12)
  • Percentage of Participants With Tobacco, Alcohol and Marijuana Use(Week 60 through Week 252)
  • Number of Participants With Tobacco, Alcohol and Marijuana Use(Week 60 through Week 252)
  • Mean Change From Baseline of Each Score Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) (Hyperactive/Impulsive, Inattentive and Total Score)(Baseline, Week 12; Baseline, Week 60; Baseline, Week 252)
  • Mean Change From Baseline of Total Score Clinical Global Impressions-Attention-Deficit/Hyperactivity Disorder-Severity (CGI-ADHD-S)(Baseline, Week 12; Baseline, Week 60; Baseline, Week 252)
  • Mean Change of Total Score Teacher-rated Swanson Nolan, and Pelham Rating Scale-Revised (SNAP-IV) ADHD Subscales (Hyperactive/Impulsive, Inattentive and Total Score)(Baseline, Week 12)
  • Mean Change From Baseline of Each Total Score Conners Comprehensive Behavior Rating Scales (CP-CBRS) Diagnostic and Statistical Manual of Mental Disorders, 4th Ed, Text Revision (DSM-IV-TR) for Symptom Subscales Manic Episode and Mixed Episode(Baseline, Week 60; Baseline, Week 252)
  • Mean Change From Baseline of Each Total Score CP-CBRS (DSM-IV-TR) ADHD Symptom Subscales (Hyperactive/Impulsive and Inattentive)(Baseline, Week 12; Baseline, Week 60; Baseline, Week 252)
  • Mean Change From Baseline of Each Total Score CP-CBRS DSM-IV-TR for Oppositional Defiant Disorder (ODD), Anxiety, Conduct Disorder and Major Depressive Episode(Baseline, Week 12; Baseline, Week 60; Baseline, Week 252)
  • Mean Change From Baseline of Each Raw Score CP-CBRS Impairment Items Subscales for Schoolwork/Grades, Friendship/Relationships, and Home Life(Baseline, Week 12; Baseline, Week 60; Baseline, Week 252)
  • Mean Change From Baseline of Each Total Score CP-CBRS Content Subscale for Aggressive Behaviors, Academic Difficulties, Social Problems, and Violence Potential)(Baseline, Week 12; Baseline, Week 60; Baseline, Week 252)
  • Mean Change From Baseline of the 5 Domain Scores Child Health and Illness Profile-Adolescent Edition (CHIP-AE) in 5 Health Outcome Domains (Satisfaction, Comfort, Resilience, Risk Avoidance and Achievement)(Baseline, Week 12; Baseline, Week 60; Baseline, Week 156)
  • Mean Change From Baseline of the 5 Domain Scores Child Health and Illness Profile-Child Edition (CHIP-CE) in 5 Health Outcome Domains (Satisfaction, Comfort, Resilience, Risk Avoidance and Achievement)(Baseline, Week 12; Baseline, Week 60; Baseline, Week 156)
  • Mean Change From Baseline of Total Score Euro-Qol Questionnaire - 5 Dimensions 3 Levels (EQ-5D-3L) Health State for Parent(Baseline, Week 12; Baseline, Week 60; Baseline, Week 252)
  • Mean Change From Baseline of Total Score EQ-5D-3L Visual Analog Scale (VAS) for Parent(Baseline, Week 12; Baseline, Week 60; Baseline, Week 252)
  • Mean Change of From Baseline Total Score EQ-5D-3L Health State for Child(Baseline, Week 12; Baseline, Week 60; Baseline, Week 252)
  • Mean Change of From Baseline Total Score EQ-5D-3L VAS for Child(Baseline, Week 12; Baseline, Week 60; Baseline, Week 252)
  • Mean Change From Baseline of Total Score EQ-5D-3L Health State for Adolescent(Baseline, Week 12; Baseline, Week 60; Baseline, Week 252)
  • Mean Change From Baseline of Total Score EQ-5D-3L VAS(Baseline, Week 12; Baseline, Week 60; Baseline, Week 252)
  • Mean Change From Baseline of Total Score Woodcock Johnson III Test of Achievement ([WJ III ACH])(Baseline, Week 60)
  • Mean Change From Baseline of Total Score Wide Range Achievement Test (WRAT 4)(Baseline, Week 60)
  • Mean Change From Baseline of Total Score Wechsler Intelligence Scale for Children Fourth Edition (WISC-IV)(Baseline, Week 60)
  • Mean Change From Baseline of Total Score Wechsler Adult Intelligence Scale - Third Edition (WAIS-III)(Baseline, Week 60)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

A Study of Pediatric Participants With Attention... | 临床试验